Avalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa

Reuters03-23

Avalo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa

Avalo outlined its focus on developing IL-1β therapies for immune-mediated inflammatory diseases, with abdakibart (AVTX-009) as its lead anti-IL-1β monoclonal antibody.
The company said enrollment is complete in the Phase 2 LOTUS trial in hidradenitis suppurativa, with topline data expected in Q2 2026.
LOTUS is designed to evaluate two dosing regimens—600 mg then 300 mg subcutaneous every 4 weeks, and 300 mg then 150 mg subcutaneous every 2 weeks—versus placebo in about 250 participants.
The primary endpoint is the percentage of participants achieving HiSCR75 at 16 weeks.
Avalo said it expects its cash runway to extend into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621770700?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621770700","market":"us","top_or_hot":-1,"title":"Avalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Avalo outlined its focus on developing IL-1β therapies for immune-mediated inflammatory diseases, with abdakibart (AVTX-009) as its lead anti-IL-1β monoclonal antibody.\n        </li>\n<li>\n          The company said enrollment is complete in the Phase 2 LOTUS trial in hidradenitis suppurativa, with topline data expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n<li>\n          LOTUS is designed to evaluate two dosing regimens—600 mg then 300 mg subcutaneous every 4 weeks, and 300 mg then 150 mg subcutaneous every 2 weeks—versus placebo in about 250 participants.\n        </li>\n<li>\n          The primary endpoint is the percentage of participants achieving HiSCR75 at 16 weeks.\n        </li>\n<li>\n          Avalo said it expects its cash runway to extend into 2028.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a>. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Avalo outlined its focus on developing IL-1β therapies for immune-mediated inflammatory diseases, with abdakibart (AVTX-009) as its lead anti-IL-1β monoclonal antibody.\n        </li>\n<li>\n          The company said enrollment is complete in the Phase 2 LOTUS trial in hidradenitis suppurativa, with topline data expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n<li>\n          LOTUS is designed to evaluate two dosing regimens—600 mg then 300 mg subcutaneous every 4 weeks, and 300 mg then 150 mg subcutaneous every 2 weeks—versus placebo in about 250 participants.\n        </li>\n<li>\n          The primary endpoint is the percentage of participants achieving HiSCR75 at 16 weeks.\n        </li>\n<li>\n          Avalo said it expects its cash runway to extend into 2028.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a>. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVTX","symbol_name":"Avalo Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLb6KSJJ:1","article_id":"2621770700","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621770700","pubTimestamp":1774265656,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avalo outlined its focus on developing IL-1β therapies for immune-mediated inflammatory diseases, with abdakibart  as its lead anti-IL-1β monoclonal antibody.The company said enrollment is complete in the Phase 2 LOTUS trial in hidradenitis suppurativa, with topline data expected in Q2 2026.LOTUS is designed to evaluate two dosing regimens—600 mg then 300 mg subcutaneous every 4 weeks, and 300 mg then 150 mg subcutaneous every 2 weeks—versus placebo in about 250 participants.The primary endpoint is the percentage of participants achieving HiSCR75 at 16 weeks.Avalo said it expects its cash runway to extend into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVTX":"Avalo Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Avalo Therapeutics发布关于abdakibart IL-1 β治疗化脓性汗腺炎的公司演示文稿","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTX":0.9},"content_text":"Avalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa\n    \n\n\n          Avalo outlined its focus on developing IL-1β therapies for immune-mediated inflammatory diseases, with abdakibart (AVTX-009) as its lead anti-IL-1β monoclonal antibody.\n        \n\n          The company said enrollment is complete in the Phase 2 LOTUS trial in hidradenitis suppurativa, with topline data expected in Q2 2026.\n        \n\n          LOTUS is designed to evaluate two dosing regimens—600 mg then 300 mg subcutaneous every 4 weeks, and 300 mg then 150 mg subcutaneous every 2 weeks—versus placebo in about 250 participants.\n        \n\n          The primary endpoint is the percentage of participants achieving HiSCR75 at 16 weeks.\n        \n\n          Avalo said it expects its cash runway to extend into 2028.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621770700","isCrawlerRequest":true}